

Ming Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8142407/publications.pdf>

Version: 2024-02-01

86

papers

14,440

citations

57758

44

h-index

62596

80

g-index

89

all docs

89

docs citations

89

times ranked

27271

citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6, 117-127.	16.8	1,693
3	Targeting cellular metabolism to improve cancer therapeutics. Cell Death and Disease, 2013, 4, e532-e532.	6.3	830
4	The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Letters, 2015, 356, 156-164.	7.2	541
5	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 2004, 6, 459-469.	16.8	497
6	MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression. Journal of Biological Chemistry, 2010, 285, 21496-21507.	3.4	370
7	Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase. Molecular Cell, 1998, 2, 581-591.	9.7	335
8	Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol. Molecular Cancer, 2010, 9, 33.	19.2	307
9	Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism. Frontiers in Immunology, 2018, 9, 1605.	4.8	298
10	Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. Clinical Cancer Research, 2004, 10, 6779-6788.	7.0	293
11	ErbB2 Promotes Src Synthesis and Stability: Novel Mechanisms of Src Activation That Confer Breast Cancer Metastasis. Cancer Research, 2005, 65, 1858-1867.	0.9	264
12	Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism. Cancer Research, 2011, 71, 4585-4597.	0.9	230
13	Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene, 2009, 28, 3689-3701.	5.9	223
14	The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy. Oncotarget, 2017, 8, 57813-57825.	1.8	190
15	Glucose Oxidation Modulates Anoikis and Tumor Metastasis. Molecular and Cellular Biology, 2012, 32, 1893-1907.	2.3	186
16	ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells. Cancer Research, 2006, 66, 2028-2037.	0.9	182
17	Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget, 2014, 5, 8202-8210.	1.8	127
18	Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 Inhibits p34Cdc2 Activation and Is Involved in Resistance to Taxol-Induced Apoptosis. Molecular Cell, 2002, 9, 993-1004.	9.7	124

#	ARTICLE	IF	CITATIONS
19	Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance. <i>Advances in Experimental Medicine and Biology</i> , 2007, 608, 119-129.	1.6	123
20	Heat Shock Factor 1 (HSF1) Controls Chemoresistance and Autophagy through Transcriptional Regulation of Autophagy-related Protein 7 (ATG7). <i>Journal of Biological Chemistry</i> , 2013, 288, 9165-9176.	3.4	121
21	High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. <i>Cancer</i> , 2004, 100, 1724-1733.	4.1	118
22	Selective Inhibition of ErbB2-Overexpressing Breast Cancer In vivo by a Novel TAT-Based ErbB2-Targeting Signal Transducers and Activators of Transcription 3-Blocking Peptide. <i>Cancer Research</i> , 2006, 66, 3764-3772.	0.9	118
23	B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 960-971.	4.1	118
24	Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance. <i>Cancer Research</i> , 2013, 73, 2709-2717.	0.9	115
25	Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis. <i>Cell Death and Disease</i> , 2013, 4, e504-e504.	6.3	113
26	Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1 α . <i>Cancer Research</i> , 2016, 76, 2231-2242.	0.9	107
27	B7-H3 in Cancer – Beyond Immune Regulation. <i>Trends in Cancer</i> , 2018, 4, 401-404.	7.4	104
28	Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism. <i>Nature Communications</i> , 2012, 3, 1271.	12.8	96
29	LOC401317, a p53-Regulated Long Non-Coding RNA, Inhibits Cell Proliferation and Induces Apoptosis in the Nasopharyngeal Carcinoma Cell Line HNE2. <i>PLoS ONE</i> , 2014, 9, e110674.	2.5	93
30	Upregulation and activation of PKC δ by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC δ and Src inhibitors. <i>Oncogene</i> , 2006, 25, 3286-3295.	5.9	90
31	Regulation of mitochondrial functions by protein phosphorylation and dephosphorylation. <i>Cell and Bioscience</i> , 2016, 6, 25.	4.8	85
32	Interplay between Immune Checkpoint Proteins and Cellular Metabolism. <i>Cancer Research</i> , 2017, 77, 1245-1249.	0.9	82
33	Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance. <i>Clinical Cancer Research</i> , 2009, 15, 1326-1334.	7.0	74
34	A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. <i>Nature Communications</i> , 2016, 7, 12885.	12.8	72
35	Emerging Metabolic Targets in Cancer Therapy. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1844.	3.0	70
36	Panepoxydione Targets NF- κ B and FOXM1 to Inhibit Proliferation, Induce Apoptosis and Reverse Epithelial to Mesenchymal Transition in Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e98370.	2.5	70

#	ARTICLE	IF	CITATIONS
37	Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation. <i>Oncogene</i> , 2019, 38, 88-102.	5.9	67
38	Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. <i>Oncotarget</i> , 2016, 7, 6891-6901.	1.8	63
39	p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53. <i>Cancer Science</i> , 2019, 110, 939-949.	3.9	56
40	Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. <i>Cancer Research</i> , 1999, 59, 1620-5.	0.9	56
41	miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma. <i>Cell Death and Disease</i> , 2016, 7, e2156-e2156.	6.3	55
42	miR-125b Functions as a Key Mediator for Snail-induced Stem Cell Propagation and Chemoresistance. <i>Journal of Biological Chemistry</i> , 2013, 288, 4334-4345.	3.4	54
43	Knockout of BRD7 results in impaired spermatogenesis and male infertility. <i>Scientific Reports</i> , 2016, 6, 21776.	3.3	46
44	Epstein-Barr virus-encoded small RNA 1 (EBER-1) could predict good prognosis in nasopharyngeal carcinoma. <i>Clinical and Translational Oncology</i> , 2016, 18, 206-211.	2.4	46
45	Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers. <i>Oncotarget</i> , 2015, 6, 662-678.	1.8	44
46	Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). <i>PLoS ONE</i> , 2015, 10, e0133072.	2.5	43
47	Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients. <i>Oncology Letters</i> , 2017, 13, 867-874.	1.8	42
48	SON and Its Alternatively Spliced Isoforms Control MLL Complex-Mediated H3K4me3 and Transcription of Leukemia-Associated Genes. <i>Molecular Cell</i> , 2016, 61, 859-873.	9.7	41
49	BRD7 plays an anti-inflammatory role during early acute inflammation by inhibiting activation of the NF- κ B signaling pathway. <i>Cellular and Molecular Immunology</i> , 2017, 14, 830-841.	10.5	40
50	Mitochondrial DNA Repair through OGG1 Activity Attenuates Breast Cancer Progression and Metastasis. <i>Cancer Research</i> , 2016, 76, 30-34.	0.9	39
51	Hypoxia induces cancer cell-specific chromatin interactions and increases MALAT1 expression in breast cancer cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 11213-11224.	3.4	39
52	MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression. <i>Oncotarget</i> , 2016, 7, 23668-23683.	1.8	36
53	Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation. <i>Oncotarget</i> , 2016, 7, 25113-25124.	1.8	34
54	Identification of candidate biomarkers for the early detection of nasopharyngeal carcinoma by quantitative proteomic analysis. <i>Journal of Proteomics</i> , 2014, 109, 162-175.	2.4	32

#	ARTICLE	IF	CITATIONS
55	ErbB2-intronic MicroRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signaling. <i>Cell Death and Disease</i> , 2015, 6, e1742-e1742.	6.3	31
56	Lactotransferrin could be a novel independent molecular prognosticator of nasopharyngeal carcinoma. <i>Tumor Biology</i> , 2015, 36, 675-683.	1.8	28
57	OmniSearch: a semantic search system based on the Ontology for MicroRNA Target (OMIT) for microRNA-target gene interaction data. <i>Journal of Biomedical Semantics</i> , 2016, 7, 25.	1.6	27
58	High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel. <i>PLoS ONE</i> , 2015, 10, e0138955.	2.5	27
59	BRD7 inhibits the Warburg effect and tumor progression through inactivation of HIF1 α /LDHA axis in breast cancer. <i>Cell Death and Disease</i> , 2018, 9, 519.	6.3	24
60	miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. <i>Oncotarget</i> , 2016, 7, 78667-78679.	1.8	23
61	Coamplification of <i>miR-4728</i> protects <i>HER2</i> -amplified breast cancers from targeted therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2594-E2603.	7.1	23
62	<i>SPLUNC1</i> is associated with nasopharyngeal carcinoma prognosis and plays an important role in all-trans-retinoic acid-induced growth inhibition and differentiation in nasopharyngeal cancer cells. <i>FEBS Journal</i> , 2014, 281, 4815-4829.	4.7	21
63	LATS kinase-mediated CTCF phosphorylation and selective loss of genomic binding. <i>Science Advances</i> , 2020, 6, eaaw4651.	10.3	21
64	Inactivation of BRD7 results in impaired cognitive behavior and reduced synaptic plasticity of the medial prefrontal cortex. <i>Behavioural Brain Research</i> , 2015, 286, 1-10.	2.2	20
65	Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. <i>Clinical Cancer Research</i> , 1998, 4, 1985-94.	7.0	20
66	APLN is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K/Akt/mTOR signaling. <i>FASEB Journal</i> , 2019, 33, 11959-11972.	0.5	19
67	OMIT: Dynamic, Semi-Automated Ontology Development for the microRNA Domain. <i>PLoS ONE</i> , 2014, 9, e100855.	2.5	18
68	OMIT: A Domain-Specific Knowledge Base for MicroRNA Target Prediction. <i>Pharmaceutical Research</i> , 2011, 28, 3101-3104.	3.5	14
69	Cancer Metabolism: Targeting metabolic pathways in cancer therapy. <i>Cancer Letters</i> , 2015, 356, 147-148.	7.2	12
70	A semantic approach for knowledge capture of MicroRNA-Target gene interactions. , 2015, , .		10
71	The Non-Coding RNA Ontology (NCRO): a comprehensive resource for the unification of non-coding RNA biology. <i>Journal of Biomedical Semantics</i> , 2016, 7, 24.	1.6	10
72	The development of non-coding RNA ontology. <i>International Journal of Data Mining and Bioinformatics</i> , 2016, 15, 214.	0.1	9

#	ARTICLE	IF	CITATIONS
73	An ontology-based MicroRNA knowledge sharing and acquisition framework. , 2012, , .		6
74	Preparation of polyclonal antibody highly specific for mouse BRD7 protein and its application. Acta Biochimica Et Biophysica Sinica, 2014, 46, 163-166.	2.0	5
75	Knowledge acquisition, semantic text mining, and security risks in health and biomedical informatics. World Journal of Biological Chemistry, 2012, 3, 27.	4.3	5
76	Ontology for MicroRNA Target prediction in human cancer. , 2010, , .		4
77	Testing for Differentially-Expressed MicroRNAs with Errors-in-Variables Nonparametric Regression. PLoS ONE, 2012, 7, e37537.	2.5	3
78	Determination of Breast Cancer Cell Migratory Ability. Methods in Molecular Biology, 2016, 1406, 171-180.	0.9	3
79	OMIT: Domain Ontology and Knowledge Acquisition in MicroRNA Target Prediction. Lecture Notes in Computer Science, 2010, , 1160-1167.	1.3	3
80	Exploiting multi-layered vector spaces for signal peptide detection. International Journal of Data Mining and Bioinformatics, 2015, 13, 141.	0.1	2
81	Epithelialâ€Mesenchymal Transition Suppresses AMPK and Sensitizes Cancer Cells to Pyroptosis under Energy Stress. Cells, 2022, 11, 2208.	4.1	2
82	Semi-automated microRNA ontology development based on artificial neural networks. , 2013, , .		1
83	1â€22 The Role of PTEN and Its Signalling Pathways, Including AKT, in Breast Cancer; An Assessment of Relationships With Other Prognostic Factors and With Outcome. Breast Diseases, 2005, 16, 53-54.	0.0	0
84	Real-time geological disaster monitoring with deformation parameters auto-detection technique. Proceedings of SPIE, 2009, , .	0.8	0
85	A domain ontology for the Non-Coding RNA field. , 2015, , .		0
86	Featuring the guest editor: Special issue cancer metabolism. Cancer Letters, 2015, 356, 145-146.	7.2	0